Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T20:45:27.540Z.
Calculation as of: 2026-10-06T20:45:27.540Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dce8aa4241063aa413a511fcc73ca02083e5b5875564fe7763a0d28183f25b54
EARNINGS YIELD
N/A
Market Cap
$235.97M
Earnings Yield
N/A
TTM Avg
11.64%
3Y Avg
12.85%
5Y Avg
11.39%
Market Cap
$235.08M
Earnings Yield
4.44%
TTM Avg
5.42%
3Y Avg
6.16%
5Y Avg
5.56%
Market Cap
$239.02M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$231.77M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Akebia Therapeutics, Inc. (AKBA) | $235.66M | N/A | N/A | N/A | N/A |
| SIGA Technologies, Inc. (SIGA)vs › | $235.97M | N/A | 11.64% | 12.85% | 11.39% |
| Utah Medical Products, Inc. (UTMD)vs › | $235.08M | 4.44% | 5.42% | 6.16% | 5.56% |
| BioAge Labs Inc. (BIOA)vs › | $236.82M | N/A | N/A | N/A | N/A |
| Invivyd, Inc. (IVVD)vs › | $237.57M | N/A | N/A | N/A | N/A |
| InflaRx N.V. (IFRX)vs › | $232.72M | N/A | N/A | N/A | N/A |
| High Tide Inc. (HITI)vs › | $239.01M | N/A | N/A | N/A | N/A |
| Century Therapeutics, Inc. (IPSC)vs › | $239.02M | N/A | N/A | N/A | N/A |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $231.77M | N/A | N/A | N/A | N/A |
| MacroGenics, Inc. (MGNX)vs › | $231.37M | N/A | 5.21% | 5.21% | 5.21% |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
